诚达药业股份有限公司 关于变更公司注册资本、修订《公司章程》并办理工商变 更登记的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 诚达药业股份有限公司（以下简称"公司"）于 2023 年 8 月 21 日召开第 五届董事会第三次会议，审议通过《关于变更公司注册资本、修订<公司章程>并 办理工商变更登记的议案》，该议案尚需提交公司股东大会审议。现将相关事项 公告如下： 一、公司注册资本变更情况 证券代码：301201 证券简称：诚达药业 公告编号：2023-041 | | 修订前 | 修订后 | | | | --- | --- | --- | --- | --- | | 第六条 | 公司注册资本为人民币 9,669.6140 | 第 六 公 司 注 册 资 本 为 人 民 币 | 条 | | | 万元。 | | 15,471.3824 万元 | | | | 第二十条 | 首次公开发行股票后，公司的股 | 第二十条 公司股份总数为 | | 154,713,824 | | 份总数为 | 9,669.6140 万股，全部为人民币 | 股，全部为人民币普通股。 | ...

证券代码：301201 证券简称：诚达药业 公告编号：2023-037 诚达药业股份有限公司 第五届董事会第三次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 表决结果：7 票同意，0 票反对，0 票弃权。 （二）审议通过《关于<2023 年半年度募集资金存放与使用情况专项报告> 的议案》 具体内容详见公司同日披露于巨潮资讯网（http://www.cninfo.com.cn）的 《2023 年半年度募集资金存放与使用情况专项报告》。 诚达药业股份有限公司（以下简称"公司"）第五届董事会第三次会议于 2023 年 8 月 21 日在公司会议室以现场结合通讯的方式召开。会议通知已于 2023 年 8 月 11 日通过电话、邮件的方式送达全体董事。本次会议应出席董事 7 人，实际 出席董事 7 人，其中董事俞毅、崔孙良以通讯方式出席会议，公司监事、高级管 理人员列席会议。会议由董事长葛建利女士召集和主持。本次会议的召集和召开 符合有关法律、行政法规、部门规章和《公司章程》的规定，形成的决议合法有 效。 二、董事会会议审议情况 ...

证券代码：301201 证券简称：诚达药业 公告编号：2023-038 诚达药业股份有限公司 第五届监事会第三次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 诚达药业股份有限公司（以下简称"公司"）第五届监事会第三次会议于 2023 年 8 月 21 日在公司会议室以现场方式召开。会议通知已于 2023 年 8 月 11 日通 过电话、邮件的方式送达各位监事。本次会议应出席监事 3 人，实际出席监事 3 人。会议由监事会主席陈维汉先生主持，董事会秘书列席会议。 会议召开、召集符合有关法律、行政法规、部门规章和《公司章程》的规定， 形成的决议合法有效。 二、监事会会议审议情况 （一）审议通过《关于<2023 年半年度报告>及其摘要的议案》 经审核，监事会认为：公司董事会编制和审核的 2023 年半年度报告全文及 摘要的程序符合法律、行政法规、中国证监会和深圳证券交易所的规定，报告内 容真实、准确、完整地反映了公司的实际情况，不存在任何虚假记载、误导性陈 述或者重大遗漏。 具体内容详见公司同日披露于巨潮资讯网（http:// ...

证券代码：301201 证券简称：诚达药业 公告编号：2023-042 诚达药业股份有限公司 关于召开2023年第二次临时股东大会的通知 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、召开会议的基本情况 （一）股东大会届次：2023年第二次临时股东大会 （二）股东大会的召集人：公司董事会 公司于2023年8月21日召开的第五届董事会第三次会议审议通过了《关于召开2023 年第二次临时股东大会的议案》，决议召开本次股东大会。 （三）会议召开的合法、合规性：本次股东大会的召开符合有关法律、行政法规、 部门规章、规范性文件、深圳证券交易所业务规则和公司章程等的规定。 （四）会议召开的日期、时间： 1、现场会议时间：2023年9月7日（星期四）下午14：00 2、网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时间为2023 年9月7日的交易时间，即9:15-9:25、9:30—11:30和13:00—15:00；通过深圳证券交 易所互联网投票的具体时间为：2023年9月7日9:15—15:00。 （五）会议的召开方式：本次股东大会采用现场表决与网络投 ...

证券代码：301201 证券简称：诚达药业 诚达药业股份有限公司 投资者关系活动记录表 编号：2023-003 | 投资者关系活动类别 | ☐特定对象调研 ☐分析师会议 | | --- | --- | | | ☐媒体采访 业绩说明会 | | | ☐新闻发布会 ☐路演活动 | | | ☐现场参观 | | | ☐其他（请文字说明其他活动内容） | | | 线上参与公司2022年度业绩说明会的全体投资者 | | 参与单位名称及人员姓名 | | | 时间 | 2023年05月12日 15:00-17:00 | | 地点 | 价值在线（https://www.ir-online.cn/）网络互动 | | | 董事长 葛建利女士 董事、总经理 卢刚先生 | | | 独立董事 汪萍女士 | | 上市公司接待人员姓名 | 副总经理、董事会秘书 杨晓静女士 | | | 财务总监 费超先生 | | | 保荐代表人 杨科先生 | | | 1.高溢价减持，接盘的是谁？当中有没有利益输送？2.公司有 | | | 没有欺诈发行，股价5月5日比发行价亏损达40%以上？3.公司有没有 | | 投资者关系活动主要内容 | 预期稳定股价的措施 ...

重要内容提示： 证券代码：301201 证券简称：诚达药业 公告编号：2023-025 诚达药业股份有限公司 关于举办2022年度业绩说明会的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 会议召开地点：价值在线（www.ir-online.cn） 会议召开方式：网络互动方式 二、参加人员 董事长 葛建利女士，董事、总经理 卢刚先生，独立董事 汪萍女士，副总 经理、董事会秘书 杨晓静女士，财务总监 费超先生，保荐代表人 杨科先生（如 遇特殊情况，参会人员可能进行调整）。 三、投资者参加方式 诚达药业股份有限公司（以下简称"公司"）已于 2023 年 4 月 24 日在巨潮 资讯网（www.cninfo.com.cn）上披露了《2022 年年度报告》及《2022 年年度报 告摘要》。为便于广大投资者更加全面深入地了解公司经营业绩、发展战略等情 况，公司定于 2023 年 5 月 12 日（星期五）15:00-17:00 在"价值在线"（www.ir- online.cn）举办公司 2022 年度业绩说明会，与投资者进行沟通和交流，广泛听取 投资者的意见和建 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥102,199,584.64, a decrease of 5.91% compared to ¥108,619,193.47 in the same period last year[5] - Net profit attributable to shareholders was ¥19,644,988.66, down 25.10% from ¥26,229,854.86 year-on-year[5] - Basic and diluted earnings per share decreased by 31.33% to ¥0.2032 from ¥0.2959 in the same period last year[5] - The company reported a net profit margin decline due to increased costs, impacting overall profitability[22] - The net profit for the first quarter of 2023 was CNY 19,620,310.26, a decrease of 25.2% compared to CNY 26,213,014.63 in the same period last year[23] - Operating profit for the first quarter was CNY 23,929,664.90, down from CNY 30,931,613.34, reflecting a decline of 22.6% year-over-year[23] - Total comprehensive income for the first quarter was CNY 19,620,310.26, compared to CNY 26,213,014.63, indicating a decline of 25.2%[24] Cash Flow and Investments - The net cash flow from operating activities increased significantly by 679.23%, reaching ¥68,175,884.92 compared to ¥8,749,113.60 in the previous year[5] - Cash flow from operating activities showed a significant increase to CNY 68,175,884.92, compared to CNY 8,749,113.60 in the previous year, representing a growth of 678.5%[27] - Cash flow from investing activities generated a net inflow of CNY 739,885,063.10, a substantial improvement from a net outflow of CNY 843,462,046.94 in the same period last year[27] Assets and Liabilities - Total assets at the end of Q1 2023 were ¥2,355,840,310.21, reflecting a 1.46% increase from ¥2,321,895,635.83 at the end of the previous year[5] - Total liabilities rose to ¥119,950,037.07, up from ¥105,811,942.95 at the beginning of the year[20] - Shareholders' equity totaled ¥2,235,890,273.14, an increase from ¥2,216,083,692.88 at the start of the year[20] - Cash and cash equivalents increased by 133.77% to ¥1,412,968,938.23, primarily due to the redemption of structured deposits[10] - Cash and cash equivalents at the end of Q1 2023 were ¥1,412,968,938.23, compared to ¥604,430,176.14 at the beginning of the year[18] Shareholder Information - The total number of common shareholders at the end of the reporting period is 16,723[12] - The largest shareholder, Ge Jianli, holds 27.17% of the shares, totaling 26,269,600 shares[12] - The second-largest shareholder, Huang Honglin, owns 12.62% of the shares, amounting to 12,205,000 shares[12] - The top ten shareholders collectively hold significant stakes, with the third-largest being Shenzhen Shengtai Investment Management Co., holding 11.24% or 10,869,900 shares[12] - The company has a total of 0 preferred shareholders with voting rights at the end of the reporting period[12] - The total number of shares held by the top ten unrestricted shareholders is 10,869,900 shares[13] - The company has a total of 26,269,600 shares under lock-up for Ge Jianli, which will be released on July 20, 2025[15] - The company has 15,500,000 shares under lock-up for Shenzhen Shengtai Investment Management, which were released on January 20, 2023[15] - The total number of shares held by the top ten shareholders with restricted shares is 26,269,600 shares[15] - The company has a total of 3,800,000 shares under lock-up for Jiaxing Maiter Equity Investment Partnership, which will be released on January 20, 2023[15] Operating Costs and Expenses - Total operating costs increased to ¥88,542,464.12, up 11.5% from ¥79,398,196.77 in Q1 2022[22] - Operating costs included ¥64,935,683.33 in cost of goods sold, which rose significantly from ¥52,567,074.55 year-over-year[22] - The company reported a decrease in sales expenses by 39.18%, amounting to ¥1,008,413.89, due to reduced commissions and freight costs[9] - Research and development expenses were CNY 4,757,398.07, slightly down from CNY 4,979,563.71, indicating a decrease of 4.4%[23] Other Notable Information - The company experienced a 220.82% increase in prepayments, totaling ¥18,114,750.67, attributed to higher material prepayments[10] - The company’s contract liabilities increased by 86.03% to ¥11,500,872.18, indicating a rise in advance payments received[10] - The company did not report any new product launches or significant market expansion strategies during this quarter[28]

Dividend and Profit Distribution - The company plans to distribute a cash dividend of 3 RMB per 10 shares to all shareholders, based on a total of 96,696,140 shares[5]. - The company has a profit distribution plan that includes a capital reserve conversion of 6 shares for every 10 shares held by shareholders[5]. - The total distributable profit for the year was RMB 320,243,039.89, with the cash dividend representing 100% of the profit distribution[160]. - The company distributed a cash dividend of RMB 4.50 per 10 shares, totaling RMB 43,513,263, based on a total share capital of 96,696,140 shares for the 2021 fiscal year[158]. - For the 2022 fiscal year, the company plans to distribute a cash dividend of RMB 3.00 per 10 shares, amounting to RMB 29,008,842, while also increasing share capital by 6 shares for every 10 shares held, resulting in a total share capital of 154,713,824 shares[160]. Financial Performance - The company's revenue for 2022 was ¥411,463,537.32, a decrease of 1.03% compared to ¥415,725,787.55 in 2021[26]. - The net profit attributable to shareholders for 2022 was ¥106,484,248.46, representing a 6.02% increase from ¥100,435,615.97 in 2021[26]. - The net profit after deducting non-recurring gains and losses was ¥68,654,409.79, down 28.01% from ¥95,370,415.47 in 2021[26]. - The total assets at the end of 2022 reached ¥2,321,895,635.83, a significant increase of 239.84% from ¥683,227,154.78 at the end of 2021[26]. - The basic earnings per share for 2022 was ¥1.1247, a decrease of 18.79% compared to ¥1.3849 in 2021[26]. - The cash flow from operating activities for 2022 was ¥47,665,536.21, down 42.67% from ¥83,140,534.53 in 2021[26]. - In 2022, the company achieved operating revenue of CNY 411.46 million and a net profit attributable to shareholders of CNY 106.48 million[56]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB for the year, representing a 15% year-over-year growth[138]. - The company reported a total revenue of 1.5 billion RMB for the fiscal year 2022, representing a year-over-year increase of 20%[198]. Market and Industry Outlook - The company operates in the CDMO industry, which is experiencing rapid growth due to the specialization and globalization of the pharmaceutical industry[36]. - The company plans to expand its market presence in the CDMO sector, focusing on both chemical and biological drug services[36]. - The global pharmaceutical R&D investment increased from $165.1 billion in 2017 to $224.1 billion in 2021, with a CAGR of 7.9%, expected to reach $306.8 billion by 2025 and $417.7 billion by 2030[37]. - The global CDMO market grew from $39.4 billion in 2017 to $63.2 billion in 2021, with a CAGR of 12.5%, projected to reach $124.3 billion by 2025 and $231.0 billion by 2030[37]. - China's CDMO market expanded from ¥13.2 billion in 2017 to ¥47.3 billion in 2021, with a CAGR of 37.7%, anticipated to reach ¥157.1 billion by 2025 and ¥355.9 billion by 2030[38]. - The share of China's CDMO market in the global market increased from 5.0% in 2017 to 13.2% in 2021, expected to account for one-fifth of the global market post-2025[38]. Research and Development - R&D expenses for the year amounted to CNY 19.44 million, representing a year-on-year increase of 12.89%[58]. - The company developed 49 new products during the reporting period, with 3 products passing the Zhejiang Province industrial new product acceptance[58]. - The company is actively pursuing new product development and technological advancements to enhance its competitive edge in the market[36]. - The company is developing a rheumatoid arthritis drug (NP0908-B) with a focus on cost control and environmental issues, aiming to enhance market competitiveness[78]. - The company is expanding its portfolio with new projects aimed at treating various diseases, enhancing its market position and economic prospects[78]. - The company is enhancing its amino acid chiral source synthesis technology platform through various projects, improving its market competitiveness[81]. - Research and development expenses increased by 30% in 2022, totaling 450 million RMB, to support new technology advancements[200]. Governance and Compliance - All board members attended the meeting to review the annual report, indicating strong governance practices[5]. - The company has established a complete governance structure with specialized committees, including the Audit Committee, Nomination Committee, Compensation and Assessment Committee, and Strategy Committee, ensuring compliance with legal and regulatory requirements[124]. - The company maintains full independence in assets, personnel, finance, organization, and business operations, with no shared resources with controlling shareholders[126]. - The company has a complete and independent financial accounting system, with separate bank accounts and tax registration, ensuring independent financial decision-making[128]. - The company has not reported any penalties from regulatory authorities for its directors or management in the past three years[144]. Environmental Responsibility - The company reported a wastewater discharge of 185,777.3 tons in 2022, a decrease of 27.39% compared to 2021[171]. - The company has implemented various pollution control measures in compliance with national standards[170]. - The company has invested approximately ¥30,797,707.82 in environmental protection and management during the reporting period[188]. - The company achieved a COD removal efficiency of 93.74% and a VOCs removal efficiency of 98%[1]. - The company has a comprehensive self-monitoring plan in place, ensuring compliance with relevant laws and regulations[173]. Employee Management and Development - The company has a total of 504 employees at the end of the reporting period, with 325 in production, 115 in technical roles, and 50 in administration[155]. - The company established a performance-based compensation system that links employee salaries to company performance and individual contributions[156]. - The company has a training system that includes both internal and external training programs aimed at enhancing employee skills and organizational capabilities[157]. - The number of R&D personnel increased by 37.70% from 61 in 2021 to 84 in 2022, with a 3.44% rise in the proportion of R&D staff[84]. Strategic Initiatives - The company plans to enhance its supply chain management, aiming for a 20% improvement in delivery times[138]. - The company plans to invest 200 million RMB in digital transformation initiatives over the next two years[200]. - The company aims to strengthen its human resource management to support its development strategy and improve talent acquisition and retention[115]. - The company will continue to optimize its operational mechanisms and improve efficiency through digital transformation and enhanced management systems[115].